secwatch.observer — SEC 8-K summary
======================================

Issuer:     TFF Pharmaceuticals, Inc. (—)
CIK:        0001733413
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001213900-24-042919
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TFF Pharma Q1 net loss $5.7M, cash $3.2M; raised $6M in public offerings since March
--------------------------------------------------------------------------------

- Net loss of $5.7M improved from $7.1M in Q1 2023; R&D spend $3.6M, G&A $2.4M.
- Cash and equivalents $3.2M at March 31; completed $4.8M offering May 1, plus $1.2M in March.
- Phase 2 TFF TAC: 8/8 patients transitioned from oral; 4/4 completed 12 weeks and entered extension.
- TFF VORI: 5/6 patients achieved clinical and mycologic response; no IPA-related mortality.
- Company prioritizing TFF TAC; exploring strategic alternatives for TFF VORI; FDA feedback expected in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733413/000121390024042919/0001213900-24-042919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733413/000121390024042919/ea0206069-8k_tffpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-042919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer